Clinical Trial Update: DPYD Pharmacogenomics and Fluoropyrimidine (FP) Dose-Adjustment [Phase 4]

View source ↗

Summary

Phase 4 clinical trial update examining DPYD pharmacogenomics for fluoropyrimidine dose-adjustment; currently recruiting.

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Breast Cancer
• Colorectal Cancer
• Gastrointestinal Intraepithelial Neoplasia
• Head and Neck Cancer

Drugs mentioned

• Fluoropyrimidines (fluoropyrimidines)

Snippet

Sponsor: Rutgers, The State University of New Jersey | Conditions: Colorectal Neoplasms, Breast Neoplasms | Phase 4 | Status: RECRUITING